The mTOR Inhibitor Rapamycin Has Limited Acute Anticonvulsant Effects in Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Hartman, Adam L ^a,b   Santos, Polan ^a   Dolce, Alison ^a   Hardwick, J Marie ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; GLUCOSE; KAINIC ACID; KETONE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ELECTRIC SHOCK; EXPERIMENTAL MOUSE; MALE; MOUSE; NONHUMAN; SEIZURE; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION;

3-HYDROXYBUTYRIC ACID; ACUTE DISEASE; ANIMALS; ANTICONVULSANTS; BLOOD GLUCOSE; BLOTTING, WESTERN; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; HIPPOCAMPUS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; KAINIC ACID; MALE; MICE; PENTYLENETETRAZOLE; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6; SEIZURES; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

ANIMALIA; MAMMALIA; MUS;

EID: 84866331178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045156     Document Type: Article

References (60)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, et al. (2007) How common are the "common" neurologic disorders? Neurology 68: 326-337.
2. Russ SA, Larson K, Halfon N, (2012) A national profile of childhood epilepsy and seizure disorder. Pediatrics 129: 256-264.
3. Kwan P, Brodie MJ, (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319.
4. Berg AT, Levy SR, Testa FM, D'Souza R, (2009) Remission of epilepsy after two drug failures in children: a prospective study. Ann Neurol 65: 510-519.
5. Hartman AL, Vining EP, (2007) Clinical aspects of the ketogenic diet. Epilepsia 48: 31-42.
6. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, et al. (2008) The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 7: 500-506.
7. Laplante M, Sabatini DM, (2009) mTOR signaling at a glance. J Cell Sci 122: 3589-3594.
8. Orlova KA, Crino PB, (2010) The tuberous sclerosis complex. Ann N Y Acad Sci 1184: 87-105.
9. Zeng LH, Xu L, Gutmann DH, Wong M, (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 63: 444-453.
10. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G, (2009) Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2: 389-398.
11. Sunnen CN, Brewster AL, Lugo JN, Vanegas F, Turcios E, et al. (2011) Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 52: 2065-2075.
12. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
13. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS, (2011) A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 43: 322-329.
14. Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, et al. (2012) The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 7: e35885.
15. Zeng LH, Rensing NR, Wong M, (2009) The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 29: 6964-6972.
16. Huang X, Zhang H, Yang J, Wu J, McMahon J, et al. (2010) Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 40: 193-199.
17. Ryther RC, Wong M (2012) Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy. Curr Neurol Neurosci Rep.
18. Wong M, (2010) Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither? Epilepsy Curr 11: 66-68.
19. Buckmaster PS, Lew FH, (2011) Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 31: 2337-2347.
20. Ruegg S, Baybis M, Juul H, Dichter M, Crino PB, (2007) Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 77: 85-92.
21. Daoud D, Scheld HH, Speckmann EJ, Gorji A, (2007) Rapamycin: brain excitability studied in vitro. Epilepsia 48: 834-836.
22. Smith M, Wilcox KS, White HS, (2007) Discovery of antiepileptic drugs. Neurotherapeutics 4: 12-17.
23. Kasap B, (2011) Sirolimus in pediatric renal transplantation. Pediatr Transplant 15: 673-685.
24. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, et al. (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62: 7291-7297.
25. Hartman AL, Zheng X, Bergbower E, Kennedy M, Hardwick JM, (2010) Seizure tests distinguish intermittent fasting from the ketogenic diet. Epilepsia 51: 1395-1402.
26. Morrison RS, Wenzel HJ, Kinoshita Y, Robbins CA, Donehower LA, et al. (1996) Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci 16: 1337-1345.
27. Guertin DA, Sabatini DM, (2009) The pharmacology of mTOR inhibition. Sci Signal 2: pe24.
28. Hartman AL, Lyle M, Rogawski MA, Gasior M, (2008) Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 49: 334-339.
29. Uhlemann ER, Neims AH, (1972) Anticonvulsant properties of the ketogenic diet in mice. J Pharmacol Exp Ther 180: 231-238.
30. Samala R, Willis S, Borges K, (2008) Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. Epilepsy Res 81: 119-127.
31. McDaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M, (2011) The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia 52: e7-11.
32. Kennedy AR, Pissios P, Otu H, Roberson R, Xue B, et al. (2007) A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab 292: E1724-1739.
33. Dalby NO, Nielsen EB, (1997) Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 28: 63-72.
34. Klitgaard H, Matagne A, Gobert J, Wulfert E, (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353: 191-206.
35. Barton ME, Klein BD, Wolf HH, White HS, (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217-227.
36. Steppuhn KG, Turski L, (1993) Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther 265: 1063-1070.
37. Cramer CL, Stagnitto ML, Knowles MA, Palmer GC, (1994) Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci 54: PL271-275.
38. Kaminski RM, Banerjee M, Rogawski MA, (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46: 1097-1104.
39. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH, (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28: 167-179.
40. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G, (1999) Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 288: 960-968.
41. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41Suppl 1: S10-16.
42. Zhang X, Velumian AA, Jones OT, Carlen PL, (2000) Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41Suppl 1: S52-60.
43. Stefani A, Spadoni F, Siniscalchi A, Bernardi G, (1996) Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307: 113-116.
44. Muller-Schwarze AB, Tandon P, Liu Z, Yang Y, Holmes GL, et al. (1999) Ketogenic diet reduces spontaneous seizures and mossy fiber sprouting in the kainic acid model. Neuroreport 10: 1517-1522.
45. Zhao Q, Stafstrom CE, Fu DD, Hu Y, Holmes GL, (2004) Detrimental effects of the ketogenic diet on cognitive function in rats. Pediatr Res 55: 498-506.
46. Potter WB, O'Riordan KJ, Barnett D, Osting SM, Wagoner M, et al. (2010) Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One 5: e8996.
47. Campbell DS, Holt CE, (2001) Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32: 1013-1026.
48. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M, (2005) Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 25: 11300-11312.
49. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY, (2005) Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25: 11288-11299.
50. Chow DK, Groszer M, Pribadi M, Machniki M, Carmichael ST, et al. (2009) Laminar and compartmental regulation of dendritic growth in mature cortex. Nat Neurosci 12: 116-118.
51. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, et al. (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 99: 467-472.
52. Ran I, Laplante I, Bourgeois C, Pepin J, Lacaille P, et al. (2009) Persistent transcription- and translation-dependent long-term potentiation induced by mGluR1 in hippocampal interneurons. J Neurosci 29: 5605-5615.
53. Hou L, Klann E, (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 24: 6352-6361.
54. Auerbach BD, Osterweil EK, Bear MF, (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480: 63-68.
55. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, et al. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28: 5422-5432.
56. Wang CC, Held RG, Chang SC, Yang L, Delpire E, et al. (2011) A critical role for GluN2B-containing NMDA receptors in cortical development and function. Neuron 72: 789-805.
57. Hernandez D, Torres CA, Setlik W, Cebrian C, Mosharov EV, et al. (2012) Regulation of presynaptic neurotransmission by macroautophagy. Neuron 74: 277-284.
58. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, et al. (2010) Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465: 942-946.
59. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu, et al, (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
60. Chachua T, Yum MS, Veliskova J, Velisek L, (2011) Validation of the rat model of cryptogenic infantile spasms. Epilepsia 52: 1666-1677.